Spectral CT to check TACE response in liver cancer
Part of Cancer, Digestive system clinical trials.
This study uses a special type of CT scan (spectral CT) to see how well liver cancer has responded to a previous TACE treatment. If you've already had TACE for your liver cancer, this scan may help your doctors decide on the next steps, such as surgery or another procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have hepatocellular carcinoma (HCC), a type of liver cancer, confirmed by biopsy or imaging.
- Your liver cancer is at Barcelona Clinic Liver Cancer (BCLC) stage A or B (early or intermediate stage).
- You have already received TACE (a procedure that blocks blood flow to the tumor).
- You are scheduled for a special CT scan (spectral CT) 4 to 8 weeks after TACE.
- You are either having surgery within a week after that scan, or you will have another imaging test (DSA or MRI) or follow-up scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether measuring the liver tumor with a CT scan can help doctors plan the best treatment. It aims to improve how well the treatment works and reduce side effects.
This trial uses a special type of MRI scan to see if doctors can predict how well a liver cancer treatment (called TACE) will work for you. The scan may help doctors understand your treatment response better.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
This trial tests a new heat-sensitive embolic agent used during TACE (a procedure that blocks blood flow to tumors and delivers chemotherapy directly to the liver) for primary liver cancer. It aims to see if the agent is safe and effective for patients who need TACE treatment.
This study looks at combining TACE (a procedure that delivers chemotherapy directly to the liver) with two newer drugs — tislelizumab (immunotherapy) and lenvatinib (targeted therapy) — for people with advanced liver cancer. The goal is to see how well this combination works when used together.
Hear when a new CT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.